Boyer, Laurent http://orcid.org/0000-0003-1229-6622
Falissard, Bruno
Nuss, Philippe http://orcid.org/0000-0002-3514-4501
Collin, Cedric
Duret, Stephanie
Rabbani, Marc
De Chefdebien, Isabelle
Tonelli, Isabelle
Llorca, Pierre Michel http://orcid.org/0000-0001-7438-8990
Fond, Guillaume http://orcid.org/0000-0003-3249-2030
Funding for this research was provided by:
Otsuka Pharmaceutical Development & Commercialization Inc. H.Lundbeck A/S
Otsuka Pharmaceutical Development & Commercialization Inc. H. Lundbeck A/S
Otsuka Pharmaceutical Development & Commercialization Inc. H. Lundbeck A/S
Otsuka Pharmaceutical Development & Commercialization Inc. H. Lundbeck A/S
Otsuka Pharmaceutical Development & Commercialization Inc. H. Lundbeck A/S
Otsuka Pharmaceutical Development & Commercialization Inc. H. Lundbeck A/S
Otsuka Pharmaceutical Development & Commercialization Inc. H. Lundbeck A/S
Otsuka Pharmaceutical Development & Commercialization Inc. H. Lundbeck A/S
Otsuka Pharmaceutical Development & Commercialization Inc. H. Lundbeck A/S
Otsuka Pharmaceutical Development & Commercialization Inc. H. Lundbeck A/S
Article History
Received: 5 January 2023
Revised: 19 June 2023
Accepted: 28 June 2023
First Online: 21 July 2023
Competing interests
: LB has received honoraria and has been a consultant for Lundbeck. BF has been a consultant for Abbvie, Actelion, Allergan, Almirall, Alnylam, Amgen, Astellas, Astrazeneca, Bayer, Biogen, Biopecs, Bioproject, Biotronik, BMS, Boehringer, Celgene, Daiichi-Sankyo, Ethypharm, Forestlab, Genevrier, Genzyme, Gilead, GrĂ¼nenthal, GSK, Guerbet, HRA, IDM Pharma, Idorsia, IMS, Indivior, IQVIA, JNJ, Kephren, Lafon, Leo, Lilly, Lundbeck, Menarini, MSD, Novartis, Novonordisk, Otsuka, Pfizer, Pierre-Fabre, Recordati, Roche, Sanofi, Servier, Stallergene, Takeda, UCB, ViiV, and Wellmera. PN has received honoraria and has been an advisor to Lundbeck and Otsuka. CC and SD are employees of IQVIA, a contract research agency responsible for the operational management of the study, funded by Lundbeck. MR and IDC are full-time employees of H. Lundbeck A/S. <b>IT</b> is a full-time employee of Otsuka Pharmaceutical Development & Commercialization Inc. PML has received personal fees from Janssen, Eisai, Ethypharm, Neuraxpharm, Lundbeck, Otsuka and Sanofi, support for meetings from Eisai, Lundbeck and Ethypharm, and fees for advisory boards from Janssen, Eisai, Ethypharm, Lundbeck, MSD, Neuraxpharm, Otsuka, Roche and Sanofi. GF has received honoraria and has been a consultant for Lundbeck.
: This study was submitted to French Health Data Hub (HDH) in November 2018 and has obtained a favorable opinion from CESREES (<i>Ethical and Scientific Committee for Research, Studies and Evaluation in Public Health)</i> in January 2019. The study was then approved by the French data protection agency (CNIL) in February 2019 (registration number: 919034; authorization number: DR-2019-065). No informed consent is required for accessing SNDS data.